TMDXTransMedics Group, Inc.

Filed with the SEC on November 5, 2026 | Current Price: $80.00 (+15.98% today)

---

What Happened

TransMedics Group, Inc. filed an 8-K with the SEC on November 5, 2026, disclosing its financial results for the third quarter of fiscal year 2026 (Items 2.02 and 9.01). The company reported revenues of $444.7 million for Q3 FY2026, a figure that underscores the remarkable scaling of a business that generated just $21.7 million in revenue back in Q3 FY2022. Net income for the quarter came in at $25.7 million, with operating income of $87.3 million, signaling a meaningfully profitable operating quarter.

---

Why It Matters

The headline numbers point to a company that has been growing at a dramatic pace relative to where it stood only a few years ago. For investors, the key practical takeaways are:

• Profitability confirmed: Operating income of $87.3 million comfortably exceeds net income of $25.7 million for the quarter, indicating significant below-the-line charges (interest expense, taxes, or other items) are absorbing a portion of operating gains — investors will want to track those items closely.
• EPS delivery: Basic EPS of $2.50 and diluted EPS of $2.28 demonstrate that earnings are flowing through to shareholders on a per-share basis.
• Revenue trajectory: The jump from $21.7 million in Q3 FY2022 to $444.7 million in Q3 FY2026 reflects extraordinary growth for a medical technology company built around organ transplant logistics and its Organ Care System platform.
• Market reaction: Shares surged +15.98% to $80.00 on the day of this report, suggesting the results exceeded market expectations materially.

---

Analysis

The scale of TransMedics' revenue growth over four years — roughly a 20-fold increase — reflects the continued commercial expansion of its normothermic perfusion technology and, increasingly, its aviation logistics services supporting transplant centers. The Q3 FY2026 figures confirm the company has crossed into consistent profitability at the operating level, a milestone that has long been anticipated by observers of this niche but high-impact medical technology space.

The gap between operating income ($87.3M) and net income ($25.7M) warrants scrutiny — that roughly $61.6 million differential suggests meaningful non-operating costs that investors should probe in the full quarterly filing (Form 10-Q), which will provide line-item detail on interest expense, debt obligations, and any one-time charges.

What to watch next:

• Full 10-Q filing for a complete income statement, balance sheet, and cash flow statement — the 8-K provides only high-level figures.
• Guidance for Q4 FY2026 and any full-year updates, which will indicate whether management expects the revenue trajectory to be sustained.
• Logistics and aviation segment performance, which has been a key driver of recent revenue expansion and also a source of investor debate about margin quality.
• Capital allocation — with operating income now robust, how the company deploys cash (debt repayment, capex, M&A) becomes a central question.

The sharp single-day move in the stock price reflects just how closely this name is watched and how much the market had been pricing in uncertainty ahead of the print.

---

Disclaimer

This report is a news and informational summary based solely on data contained in TransMedics Group's SEC filing dated November 5, 2026, and publicly available market data. It does not constitute investment advice, an offer to buy or sell securities, or an equity research recommendation of any kind. No rating or price target is expressed or implied. Investors should conduct their own due diligence and consult a qualified financial professional before making any investment decisions.

Source

Filed with the SEC on 2026-11-05. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1756262/000119312526449729/tmdx-20261105.htm